Medifast (NYSE:MED) Director Acquires $500,540.00 in Stock

Medifast Inc (NYSE:MED) Director Parsa Kiai bought 43,150 shares of Medifast stock in a transaction on Thursday, August 20th. The shares were bought at an average cost of $11.60 per share, with a total value of $500,540.00. Following the acquisition, the director directly owned 661,306 shares in the company, valued at approximately $7,671,149.60. This represents a 6.98% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Parsa Kiai also recently made the following trade(s):

• On Wednesday, August 19th, Parsa Kiai purchased 29,337 shares of Medifast stock. The stock was purchased at an average cost of $11.66 per share, for a total transaction of $342,069.42.

Medifast Trading Up 0.4%

Shares of NYSE:MED opened at $12.00 on Monday. The company has a 50 day moving average of $10.92 and a 200 day moving average of $11.06. The stock has a market cap of $134.16 million, a P/E ratio of -5.15 and a beta of 0.65. Medifast Inc has a 12 month low of $9.22 and a 12 month high of $14.67.

Medifast (NYSE:MED) last announced its quarterly earnings results on Monday, August 3rd. The specialty retailer reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.37. The firm had revenue of $76.38 million during the quarter, compared to the consensus estimate of $72.70 million. Medifast had a negative net margin of 8.08% and a negative return on equity of 6.69%. Medifast has set its FY 2026 guidance at -1.750–0.250 EPS and its Q3 2026 guidance at -0.650–0.150 EPS. On average, equities analysts forecast that Medifast Inc will post -1 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Medifast

Institutional investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets lifted its holdings in shares of Medifast by 103.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,338 shares of the specialty retailer’s stock worth $32,000 after acquiring an additional 1,187 shares during the last quarter. Quantbot Technologies LP bought a new position in Medifast in the third quarter valued at $37,000. Intesa Sanpaolo Wealth Management bought a new position in Medifast in the fourth quarter valued at $47,000. State of Wyoming purchased a new stake in Medifast during the fourth quarter valued at about $59,000. Finally, Ancora Advisors LLC purchased a new stake in Medifast during the second quarter valued at about $75,000. Institutional investors own 95.51% of the company’s stock.

Analysts Set New Price Targets

MED has been the subject of several recent analyst reports. Weiss Ratings upgraded Medifast from a “sell (e+)” rating to a “sell (d)” rating in a research report on Monday, August 17th. Zacks Research cut Medifast from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 11th. Two equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Reduce” and a consensus target price of $12.00.

Medifast Company Profile

Medifast, Inc (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client’s weight‐loss journey.

Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight‐management solutions.